A2 Milk is principally engaged in the commercialization of a2 Milk™ related products as supported by the ownership of intellectual property that enables the identification of cattle for the production of a2 Milk™. Through its associated companies, Co. is also engaged in the distribution and marketing of a2 Milk™ in Australia and Japan and commercialize the sales and licensing rights for the supply, distribution and marketing of a2 Milk™ in the U.S. Co. products are also sold under the Jalna and Fresha Valley brand names. Co. operates predominantly in New Zealand and Australia.
  • TickerATM
  • ISINNZATME0002S8
  • ExchangeNZX
  • SectorFood Producers
  • CountryNew Zealand

Analysts

Adam Fleck

Morningstar | New Government Regulations Don’t Derail A2 Milk’s Growth Opportunity; Shares Fairly Valued

We don’t expect China’s proposed regulations to support its domestic infant formula market will damage the market-share opportunities we see for narrow-moat a2 Milk, and we maintain our NZD 14.50 (AUD 13.60) fair value estimate. However, the stock appears fully valued, and doesn’t offer a margin of safety to account for the potential risk of further government regulation or change in competitive dynamics. China’s National Development and Reform Commission, or NDRC, has outlined several planned measures to improve the quality and consumer confidence of domestically produced formula, with an ai...

Adam Fleck

Morningstar | New Government Regulations Don’t Derail A2 Milk’s Growth Opportunity; Shares Fairly Valued

We don’t expect China’s proposed regulations to support its domestic infant formula market will damage the market-share opportunities we see for narrow-moat a2 Milk, and we maintain our NZD 14.50 (AUD 13.60) fair value estimate. However, the stock appears fully valued, and doesn’t offer a margin of safety to account for the potential risk of further government regulation or change in competitive dynamics. China’s National Development and Reform Commission, or NDRC, has outlined several planned measures to improve the quality and consumer confidence of domestically produced formula, with an ai...

Adam Fleck

New Government Regulations Don’t Derail A2 Milk’s Growth Opportunity; Shares Fairly Valued

We don’t expect China’s proposed regulations to support its domestic infant formula market will damage the market-share opportunities we see for narrow-moat a2 Milk, and we maintain our NZD 14.50 (AUD 13.60) fair value estimate. However, the stock appears fully valued, and doesn’t offer a margin of safety to account for the potential risk of further government regulation or change in competitive dynamics. China’s National Development and Reform Commission, or NDRC, has outlined several planned m...

Adam Fleck

New Government Regulations Don’t Derail A2 Milk’s Growth Opportunity; Shares Fairly Valued

We don’t expect China’s proposed regulations to support its domestic infant formula market will damage the market-share opportunities we see for narrow-moat a2 Milk, and we maintain our NZD 14.50 (AUD 13.60) fair value estimate. However, the stock appears fully valued, and doesn’t offer a margin of safety to account for the potential risk of further government regulation or change in competitive dynamics. China’s National Development and Reform Commission, or NDRC, has outlined several planned m...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Testing 200-day MA support Generally speaking most major indexes are currently trading at the lower end of their May trading ranges. Barring improving headlines regarding tariffs & trade or comments from the Fed suggesting a potential rate cut on the horizon - both of which would result in a weaker U.S. dollar - we believe global markets are vulnerable to further weakness. With global markets in purgatory, we are watching for support at the all-important 200-day moving averages on the S&P 500, MSCI ACWI, ACWI ex-U.S., and EAFE indexes. Breakdowns below these support levels would be problemati...

Adam Fleck

Morningstar | New Government Regulations Don’t Derail A2 Milk’s Growth Opportunity; Shares Fairly Valued

We don’t expect China’s proposed regulations to support its domestic infant formula market will damage the market-share opportunities we see for narrow-moat a2 Milk, and we maintain our NZD 14.50 (AUD 13.60) fair value estimate. However, the stock appears fully valued, and doesn’t offer a margin of safety to account for the potential risk of further government regulation or change in competitive dynamics. China’s National Development and Reform Commission, or NDRC, has outlined several planned measures to improve the quality and consumer confidence of domestically produced formula, with an ai...

Adam Fleck

Morningstar | New Government Regulations Don’t Derail A2 Milk’s Growth Opportunity; Shares Fairly Valued

We don’t expect China’s proposed regulations to support its domestic infant formula market will damage the market-share opportunities we see for narrow-moat a2 Milk, and we maintain our NZD 14.50 (AUD 13.60) fair value estimate. However, the stock appears fully valued, and doesn’t offer a margin of safety to account for the potential risk of further government regulation or change in competitive dynamics. China’s National Development and Reform Commission, or NDRC, has outlined several planned measures to improve the quality and consumer confidence of domestically produced formula, with an ai...

Adam Fleck

New Government Regulations Don’t Derail A2 Milk’s Growth Opportunity; Shares Fairly Valued

We don’t expect China’s proposed regulations to support its domestic infant formula market will damage the market-share opportunities we see for narrow-moat a2 Milk, and we maintain our NZD 14.50 (AUD 13.60) fair value estimate. However, the stock appears fully valued, and doesn’t offer a margin of safety to account for the potential risk of further government regulation or change in competitive dynamics. China’s National Development and Reform Commission, or NDRC, has outlined several planned m...

Adam Fleck

New Government Regulations Don’t Derail A2 Milk’s Growth Opportunity; Shares Fairly Valued

We don’t expect China’s proposed regulations to support its domestic infant formula market will damage the market-share opportunities we see for narrow-moat a2 Milk, and we maintain our NZD 14.50 (AUD 13.60) fair value estimate. However, the stock appears fully valued, and doesn’t offer a margin of safety to account for the potential risk of further government regulation or change in competitive dynamics. China’s National Development and Reform Commission, or NDRC, has outlined several planned m...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Testing 200-day MA support Generally speaking most major indexes are currently trading at the lower end of their May trading ranges. Barring improving headlines regarding tariffs & trade or comments from the Fed suggesting a potential rate cut on the horizon - both of which would result in a weaker U.S. dollar - we believe global markets are vulnerable to further weakness. With global markets in purgatory, we are watching for support at the all-important 200-day moving averages on the S&P 500, MSCI ACWI, ACWI ex-U.S., and EAFE indexes. Breakdowns below these support levels would be problemati...

Dave Nicoski ...
  • Ross LaDuke

Int'l Insights: Developed Markets Leadership Chart Book

Europe in focus The U.S. dollar continues to grind marginally higher, and EM equities have suffered as a result. Meanwhile, RS for the MSCI EAFE index is bottoming when compared to the MSCI EM index, largely due to outperformance in Europe. With developed int'l markets beginning to outperform emerging markets, we recommend adding exposure to the developed int'l space. Below we highlight attractive and actionable themes within developed int'l: • Europe & Japan: Though this is an all-encompassing bottoms-up chart book for developed ex-U.S., make no mistake, the vast majority of today's buy rec...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch